Trendlines’ holdings in MitrAssist were sold to Wai Tech Holding Ltd. in November 2017.
MitrAssist has developed a minimally invasive approach to treating mitral regurgitation (MR). The proprietary MitrAssist implant is placed on top of the heart’s own mitral valve and works in unison with it to enhance the valve’s functionality.
MitrAssist’s “valve-in-valve” approach brings an improved, cost-effective treatment solution for all MR patients.
The novel approach offers a number of significant advantages over minimally invasive solutions, both existing and in development:
Achievement: 2014, Best Start-Up, Israel Innovation Authority (previously, Office of the Chief Scientist of the Ministry of Economy)
MR is a serious condition that occurs when the heart’s mitral valve doesn’t close tightly, which allows blood to flow backward in the heart. This failure affects the heart’s pumping efficiency, causing it to work harder and possibly leading to congestive heart failure.
Due to health- and age- related issues, millions of MR patients are not candidates for open heart surgery, the standard treatment for acute MR.